21:25 , Sep 28, 2018 |  BC Extra  |  Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Thursday, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in a...
17:33 , Sep 28, 2018 |  BC Week In Review  |  Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans to start Phase III testing of the candidate...
16:53 , Sep 26, 2018 |  BC Extra  |  Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) added $3.45 (35%) to $13.35 on Wednesday after reporting that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
19:55 , Sep 22, 2017 |  BC Week In Review  |  Financial News

Aldeyra raises $28.8M follow-on

Aldeyra Therapeutics Inc. (NASDAQ:ALDX), which focuses on diseases related to aldehydes, raised $28.8 million through the sale of 4 million shares at $7.25 in a follow-on underwritten by Cantor Fitzgerald and Laidlaw. The price is...
19:05 , Sep 19, 2017 |  BC Extra  |  Financial News

Aldeyra raises $25 million in follow-on

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) raised $25 million through the sale of 3.5 million shares at $7.25 in a follow-on underwritten by Cantor Fitzgerald and Laidlaw. The price is a 20% discount to Aldeyra’s close of...
23:56 , Sep 14, 2017 |  BC Extra  |  Financial News

Aldeyra stock surge continues

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $4.45 (70%) to $10.80 on Thursday as momentum continued following a Phase IIa data readout on Tuesday showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry...
23:34 , Sep 14, 2017 |  BC Week In Review  |  Clinical News

Aldeyra reports Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported data from a Phase IIa trial showing that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease compared to baseline. The trial enrolled 51 patients with...
20:11 , Sep 12, 2017 |  BC Extra  |  Clinical News

Aldeyra gains on Phase IIa data for dry eye candidate

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $1.40 (33%) to $5.65 on Tuesday after reporting that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease in a Phase IIa trial. Next half, the...
00:26 , May 3, 2017 |  BC Week In Review  |  Clinical News

Aldeyra starts Ph III of ADX-102 for non-infectious anterior uveitis

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) began a Phase III trial to evaluate 0.5% ADX-102 ophthalmic solution for 4 weeks in about 100 patients with non-infectious anterior uveitis. The primary endpoint of the double-blind, vehicle-controlled, U.S. trial...